Wells Fargo & Company Capricor Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 44,946 shares of CAPR stock, worth $973,080. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,946
Previous 32,562
38.03%
Holding current value
$973,080
Previous $221,000
3.17%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CAPR
# of Institutions
69Shares Held
6.34MCall Options Held
210KPut Options Held
374K-
Black Rock Inc. New York, NY1.63MShares$35.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.55MShares$33.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA642KShares$13.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny480KShares$10.4 Million0.0% of portfolio
-
State Street Corp Boston, MA401KShares$8.68 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $527M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...